---
title: "KPV: what sources report"
url: https://humanpeptides.fyi/peptides/kpv
site: humanpeptides.fyi
last_reviewed: 2026-10-11
---


# KPV

> humanpeptides.fyi makes no claims of its own. Every statement below reports what a cited source says, with its link. Not medical advice.

KPV: Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH that suppresses NF-kB/MAPK inflammatory signaling and is taken up by inflamed gut cells via the PepT1 transporter. The sources cited here most often discuss it for: Gut inflammation, animal; Mucosal healing, mice; Skin inflammation, marketing claim. Evidence label: Preclinical.

## At a glance

- **Type:** Peptide
- **Family:** Immune & Gut
- **Evidence label:** Preclinical (2 of 5)
- **Regulatory status:** Not FDA-approved; in July 2026 an FDA advisory committee voted 8-6-1 to recommend adding KPV to the 503A compounding bulks list, against FDA staff advice, but the vote is advisory and FDA's next step is notice-and-comment rulemaking.
- **Goals discussed:** Gut & Digestion, Healing & Recovery, Skin & Glow
- **Also called:** Lys-Pro-Val, lysine-proline-valine, tripeptide KPV
- **Last reviewed:** 2026-10-11

## What is KPV?

- Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH that suppresses NF-kB/MAPK inflammatory signaling and is taken up by inflamed gut cells via the PepT1 transporter; research compound, not FDA-approved, no controlled human trials. Sources: <https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/>, <https://www.restorativecompounding.com/blog/kpv-peptide-inflammation-gut-skin-research-fda-status>

**Regulatory status:** Not FDA-approved; in July 2026 an FDA advisory committee voted 8-6-1 to recommend adding KPV to the 503A compounding bulks list, against FDA staff advice, but the vote is advisory and FDA's next step is notice-and-comment rulemaking. Source: <https://www.sheppard.com/insights/blogs/compounded-peptides-on-the-loose-what-the-recent-pcac-meeting-means-for-industry>

## What is KPV researched for?

### 1. Gut inflammation, animal

- Reduces intestinal inflammation: oral KPV reduced DSS- and TNBS-induced colitis in mice via PepT1 uptake (animal study) Sources: <https://pubmed.ncbi.nlm.nih.gov/18061177/>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/>
- Goals: [Gut & Digestion](https://humanpeptides.fyi/objectives/gut)

### 2. Mucosal healing, mice

- Targeted oral KPV nanoparticles improved mucosal healing and lowered TNF-alpha in ulcerative colitis models (animal study) Sources: <https://pmc.ncbi.nlm.nih.gov/articles/PMC5498804/>, <https://hal.science/hal-04653413v1/document>
- Goals: [Gut & Digestion](https://humanpeptides.fyi/objectives/gut), [Healing & Recovery](https://humanpeptides.fyi/objectives/healing)

### 3. Skin inflammation, marketing claim

- Marketed for skin inflammation/wound healing (psoriasis, eczema); only preclinical data, poor passive skin penetration (review/blogs) Sources: <https://peptidesexplorer.com/blog/kpv-peptide-benefits>, <https://braklabs.com/peptides/kpv/>, <https://www.sciencedirect.com/science/article/abs/pii/S0022354917301740>
- Goals: [Skin & Glow](https://humanpeptides.fyi/objectives/skin)

## What do researchers and users say about KPV?

> "Intriguingly, we found that HA-KPV-NPs exert combined effects against UC by both accelerating mucosal healing and alleviating inflammation."
>
> Xiao B, et al., Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. <https://pubmed.ncbi.nlm.nih.gov/28143741/>

Context: Mouse model of ulcerative colitis using KPV packed in targeted nanoparticles (Mol Ther, 2017); not a human study.

> "FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration."
>
> US Food and Drug Administration, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. <https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>

Context: FDA safety-risk summary for KPV, listed under nominated-but-withdrawn substances on its compounding safety-risks page (content current as of April 2026).

> "I've been using it for a couple of weeks. If you have excessive gas then it most likely won't change that, but if you're having a tun of inflammation in your gut then it will work really well."
>
> Anonymous user, r/ibs, Anyone with IBS actually notice anything from KPV?. <https://www.reddit.com/r/ibs/comments/1vohbi1/anyone_with_ibs_actually_notice_anything_from_kpv/>

Context: Unverified self-report; the thread starter notes most available evidence is animal data and anecdotes.

## What side effects of KPV are reported?

- Reported GI upset, bloating, diarrhea, headaches (anecdotal Reddit) Sources: <https://www.reddit.com/r/Biohackers/comments/1rfebe7/kpv_side_effects/>, <https://www.reddit.com/r/Biohackers/comments/1s0eaup/bpc157_kpv_did_anyone_get_gi_side_effects_at_the/>
- Human dosing and safety unknown Sources: <https://www.incarenow.com/is-kpv-peptide-better-than-proven-alternatives/>
- FDA says it lacks important safety information on KPV, including whether it would cause harm in humans, because no human exposure data were identified. (regulator statement) Sources: <https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>
- Product identity is uncertain: FDA staff told its advisory panel that these peptides lack a settled chemical form, so material sold under the same name can differ between suppliers. (regulator review (advisory meeting)) Sources: <https://www.sheppard.com/insights/blogs/compounded-peptides-on-the-loose-what-the-recent-pcac-meeting-means-for-industry>

## What do peptide guides say about KPV?

- **Dr. Axe:** Dr. Axe classifies KPV as research only, with evidence limited to cells and animals. <https://draxe.com/peptides/>
- **PepEdHub:** PepEdHub describes KPV as the last three amino acids of alpha-MSH, keeping its anti-inflammatory action without activating melanocortin receptors, and lists gut inflammation and IBD as its main research interest. <https://pepedhub.com/peptides/kpv>
- **PubMed:** In human gut and immune cells, very low concentrations of KPV blocked NF-kB and MAP kinase inflammatory signaling, and oral KPV reduced chemically induced colitis in mice. <https://pubmed.ncbi.nlm.nih.gov/18061177/>
- **Sheppard (law firm analysis):** FDA scientific staff recommended against listing KPV and six other peptides for compounding in 2026, citing unsettled chemical identity, but the advisory panel voted to recommend it anyway. <https://www.sheppard.com/insights/blogs/compounded-peptides-on-the-loose-what-the-recent-pcac-meeting-means-for-industry>

## What does the research say, system by system?

### Body & tissues

- Gut: colonic epithelium and immune cells, improved barrier and mucosal healing in colitis models (animal) Sources: <https://pmc.ncbi.nlm.nih.gov/articles/PMC5498804/>
- Skin: iontophoresis/microporation needed for delivery across human skin (ex vivo) Sources: <https://www.sciencedirect.com/science/article/abs/pii/S0022354917301740>

### Hormones & physiology

- Anti-inflammatory: inhibits NF-kB and MAPK pathways, lowers pro-inflammatory cytokines (cell/animal) Sources: <https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/>

### Also notable

- Reddit users with IBS report reduced bloating/pain/urgency after 4-6 weeks of oral KPV, others no benefit (anecdotal) Sources: <https://www.reddit.com/r/ibs/comments/1vohbi1/anyone_with_ibs_actually_notice_anything_from_kpv/>, <https://www.reddit.com/r/KPVPeptide/comments/1ttywl0/has_anyone_tried_oral_kpv_for_gut_issues/>

## How strong is the evidence for KPV?

**Preclinical** (2 of 5). Animal + cell studies only; human use anecdotal

_Mostly cell and animal studies. Human effects unknown._

## Questions about KPV

### What is KPV?

Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH that suppresses NF-kB/MAPK inflammatory signaling and is taken up by inflamed gut cells via the PepT1 transporter.

### Is KPV FDA-approved?

Not FDA-approved; in July 2026 an FDA advisory committee voted 8-6-1 to recommend adding KPV to the 503A compounding bulks list, against FDA staff advice, but the vote is advisory and FDA's next step is notice-and-comment rulemaking.

### What is KPV researched for?

The sources cited on this page most often discuss three outcomes: Gut inflammation, animal; Mucosal healing, mice; Skin inflammation, marketing claim. Each line above shows what the source reports and how strong that evidence is.

### What side effects of KPV are reported?

Reported in the cited sources: Reported GI upset, bloating, diarrhea, headaches; Human dosing and safety unknown; FDA says it lacks important safety information on KPV, including whether it would cause harm in humans, because no human exposure data were identified. The list is not complete, and few listed risks does not mean a compound is safe.

### How strong is the evidence for KPV?

Evidence label: Preclinical. Animal + cell studies only; human use anecdotal.

### What else is KPV called?

Names used for it include Lys-Pro-Val, lysine-proline-valine, tripeptide KPV.

### Does humanpeptides.fyi recommend KPV?

No. humanpeptides.fyi makes no claims and no recommendations of its own. It summarizes and links to what others have published and posted. Nothing here is medical advice; talk to a licensed clinician.

---
Family: [Immune & Gut](https://humanpeptides.fyi/peptides?cat=immune). HTML version: <https://humanpeptides.fyi/peptides/kpv>. Disclaimer: <https://humanpeptides.fyi/disclaimer>